Hycor
This article was originally published in The Gray Sheet
Executive Summary
Plans to close its Portland, Maine Ventrex allergy diagnostic and immunodiagnostic product manufacturing facility by late July. The firm will consolidate the operations from the 70,000-square- foot facility into its Garden Grove, California facility. Hycor will record a one-time after-tax charge of approximately $800,000, which will include "all costs associated with the Portland facility closure, severance and outplacement programs, and the integration of Ventrex operations into the Garden Grove facility." The firm, which anticipates an eighteen-month payback on the expenses, expects that the closure and consolidation will yield annual after-tax savings of approximately $500,000.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.